Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 88-95

  Wang, Feng qiang ^a   Ariztia, Edgardo V ^a   Boyd, Leslie R ^b   Horton, Faith R ^b   Smicun, Yoel ^a   Hetherington, Jessica A ^a   Smith, Phillip J ^a   Fishman, David A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endometrial cancer; HEC 1A; Invasion; LPA; MMPs; uPA

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; LYSOPHOSPHATIDIC ACID; MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; UROKINASE;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WOUND CLOSURE; ZYMOGRAPHY;

EID: 77949305584     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.012     Document Type: Article

References (68)

1. Jemal A., et al. Cancer statistics, 2009. CA Cancer J. Clin. 59 4 (2009) 225-249
2. Homesley H.D., Boronow R.C., and Lewis Jr. J.L. Treatment of adenocarcinoma of the endometrium at Memorial-James Ewing Hospitals, 1949-1965. Obstet. Gynecol. 47 1 (1976) 100-105
3. Lotocki R.J., et al. Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am. J. Obstet. Gynecol. 146 2 (1983) 141-145
4. Abeler V.M., Kjorstad K.E., and Nesland J.M. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer 68 1 (1991) 98-105
5. Morrow C.P., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 40 1 (1991) 55-65
6. Chambers A.F., Groom A.C., and MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev., Cancer 2 8 (2002) 563-572
7. Crissman J.D. Tumor-host interactions as prognostic factors in the histologic assessment of carcinomas. Pathol. Annu. 21 Pt 1 (1986) 29-52
8. Kopfstein L., and Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell. Mol. Life Sci. 63 4 (2006) 449-468
9. Ruggieri S., et al. Lipid characteristics in metastatic cells. Clin. Exp. Metastasis 17 4 (1999) 271-276
10. Ariztia E.V., et al. The tumor microenvironment: key to early detection. Crit. Rev. Clin. Lab. Sci. 43 5-6 (2006) 393-425
11. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev., Cancer 3 8 (2003) 582-591
12. Fang X., et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta 1582 1-3 (2002) 257-264
13. Schulte K.M., et al. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int. J. Cancer 92 2 (2001) 249-256
14. Eder A.M., et al. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res. 6 6 (2000) 2482-2491
15. Furui T., et al. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin. Cancer Res. 5 12 (1999) 4308-4318
16. Goetzl E.J., and An S. A subfamily of G protein-coupled cellular receptors for lysophospholipids and lysosphingolipids. Adv. Exp. Med. Biol. 469 (1999) 259-264
17. Pustilnik T.B., et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res. 5 11 (1999) 3704-3710
18. Smicun Y., et al. S1P regulation of ovarian carcinoma invasiveness. Gynecol. Oncol. 103 3 (2006) 952-959
19. Noguchi K., Ishii S., and Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278 28 (2003) 25600-25606
20. Lee C.W., et al. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281 33 (2006) 23589-23597
21. Yanagida K., et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J. Biol. Chem. 284 26 (2009) 17731-17741
22. Xu Y., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280 8 (1998) 719-723
23. Sasagawa T., et al. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 34 1 (1999) 17-21
24. Sasagawa T., et al. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J. Nutr. Sci. Vitaminol. (Tokyo) 44 6 (1998) 809-818
25. Hope J.M., et al. LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol. Oncol. 112 1 (2009) 215-223
26. Yoshida S., et al. Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. J. Clin. Endocrinol. Metab. 87 5 (2002) 2376-2383
27. Wang F., Reierstad S., and Fishman D.A. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett. 236 2 (2006) 292-301
28. Wang F.Q., et al. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int. J. Cancer 114 1 (2005) 19-31
29. Wang F.Q., et al. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol. Oncol. 115 3 (2009) 414-423
30. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 9 (2001) e45
31. Ellerbroek S.M., et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 59 7 (1999) 1635-1641
32. Moser T.L., et al. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem. J. 307 Pt 3 (1995) 867-873
33. Bae-Jump V., et al. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol. Oncol. 73 2 (1999) 265-272
34. Fishman D.A., et al. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 61 7 (2001) 3194-3199
35. Eichholtz T., et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291 Pt 3 (1993) 677-680
36. Parrill A.L. Lysophospholipid interactions with protein targets. Biochim. Biophys. Acta 1781 9 (2008) 540-546
37. Svetlov S.I., et al. Lysophosphatidic acid induces clonal generation of mouse neurospheres via proliferation of Sca-1- and AC133-positive neural progenitors. Stem Cells Dev. 13 6 (2004) 685-693
38. Shida D., et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 63 7 (2003) 1706-1711
39. Raj G.V., et al. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J. Urol. 167 3 (2002) 1458-1463
40. Holtsberg F.W., et al. Lysophosphatidic acid induces necrosis and apoptosis in hippocampal neurons. J. Neurochem. 70 1 (1998) 66-76
41. Holtsberg F.W., et al. Lysophosphatidic acid and apoptosis of nerve growth factor-differentiated PC12 cells. J. Neurosci. Res. 53 6 (1998) 685-696
42. Tigyi G., Dyer D.L., and Miledi R. Lysophosphatidic acid possesses dual action in cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 91 5 (1994) 1908-1912
43. Kim J., Keys J.R., and Eckhart A.D. Vascular smooth muscle migration and proliferation in response to lysophosphatidic acid (LPA) is mediated by LPA receptors coupling to Gq. Cell. Signal. 18 10 (2006) 1695-1701
44. Jin Y., et al. Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization. Eur. J. Immunol. 33 8 (2003) 2083-2089
45. Jung I.D., et al. Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells. Eur. J. Biochem. 271 8 (2004) 1557-1565
46. Shida D., et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp. Cell Res. 301 2 (2004) 168-178
47. Yamada T., et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J. Biol. Chem. 279 8 (2004) 6595-6605
48. So J., et al. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol. Oncol. 95 2 (2004) 314-322
49. Ray J.M., and Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Respir. J. 7 11 (1994) 2062-2072
50. Nagase H., Visse R., and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69 3 (2006) 562-573
51. Vihinen P., Ala-aho R., and Kahari V.M. Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Targets 5 3 (2005) 203-220
52. Davidson B., et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur. J. Cancer 37 16 (2001) 2040-2049
53. Wu X., et al. Activated matrix metalloproteinase-2-a potential marker of prognosis for epithelial ovarian cancer. Gynecol. Oncol. 84 1 (2002) 126-134
54. Schmalfeldt B., et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7 8 (2001) 2396-2404
55. Davidson B., et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol. 73 3 (1999) 372-382
56. Jones J.L., Glynn P., and Walker R.A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J. Pathol. 189 2 (1999) 161-168
57. Liotta L.A., et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284 5751 (1980) 67-68
58. Graesslin O., et al. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int. J. Gynecol. Cancer 16 5 (2006) 1911-1917
59. Aglund K., et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol. Oncol. 94 3 (2004) 699-704
60. Park Y.H., et al. Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture. Int. J. Gynecol. Cancer 13 1 (2003) 53-60
61. Park D.W., et al. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecol. Oncol. 82 3 (2001) 442-449
62. Di Nezza L.A., et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94 5 (2002) 1466-1475
63. Stanton H., et al. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J. Cell. Sci. 111 Pt 18 (1998) 2789-2798
64. Imai K., et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J. Biol. Chem. 270 12 (1995) 6691-6697
65. Ueno H., et al. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int. J. Cancer 84 5 (1999) 470-477
66. Shiomi T., and Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 22 2-3 (2003) 145-152
67. Wang F.Q., et al. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Mol. Cancer Res. 4 11 (2006) 831-841
68. Yamashita K., et al. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int. J. Cancer 79 2 (1998) 187-194